Research & Education

Management of Locally Recurrent NSCLC Following SBRT

Wednesday, December 9, 2015 at 8 p.m. JST - Recording Available

The IASLC Education Committee is pleased to announce the fourth program in the 2015 series of Live Webinars presented by the Advanced Radiation Therapy (ART) Committee. This subcommittee is focused on the development and execution of educational and informational programs addressing state of the art radiation therapy for lung cancer.

Françoise MORNEX Yukinori Matsuo Hiroshi Date 

Program Chair
PR Françoise Mornex , MD, PhD

Département de Radiothérapie
Centre Hospitalier Lyon Sud
LYON, France

Yukinori Matsuo, MD, PhD

Senior Lecturer,
Department of Radiation
Oncology and Image-applied Therapy
Kyoto University
Graduate School of Medicine
Kyoto, Japan

Professor Hiroshi Date, MD
 
Chairman Department of
Thoracic Surgery
Kyoto University
Graduate School of Medicine
Kyoto, Japan

Name of Reviewer(s): 

              

Fred Hirsch, MD, PhD –Speakers Bureau/Advisory Board: Astrazeneca, Genentech, BMS, Lilly and Abbvie.

Name of Planner(s): 

 

    Deb Whippen-Nothing to Disclose

 

Name of Activity: 

 

Management of Locally Recurrent NSCLC Following SBRT

Date of Activity:

 

12/09/2015

Faculty/Speaker(s):

Financial DISCLOSURES

COI Resolution: Ensure a balanced discussion of alternative. Do not use trade names. Do not refer to company names or logos. Do not recommend therapies.

“All planning committee members’, reviewers, planners and faculty et al. identified conflicts of interest pertaining to this activity were resolved prior to the activity.”

 

Moderator – Françoise Mornex , MD, PhDConsulting for: Lilly, Roche and Boehringrt-Ingelheim

Speaker- Yukinori Matsuo, MD, PhD- Nothing to Disclose

Speaker- Professor Hiroshi Date, MD- Nothing to Disclose

Type of Activity: 

 Live Course

  Internet Live Course (Webinar)XXXX

 Internet Enduring Material

Are there Commercial Supporters for this activity?

       Yes     

If yes, please list: Grant Support from Elekta

 

Stereotactic body radiation is now considered a safe and efficient treatment for small, early stage non-small cell lung cancers. For patients with locally recurrent disease following SBRT, retreatment with SBRT may be an option for selected patients, while for other patients a surgical approach may be indicated. Of 308 patients undergoing SBRT for clinical stage I NSCLC, 49 patients were identified to have isolated local recurrence and 12 patients underwent salvage surgery. Five-year survival for patients undergoing salvage surgery was 79.5% from local recurrence. Operability based on multidisciplinary conferences, rather than measurable patient characteristics, is essential for appropriate patient selection for salvage surgery.

Diagnosis of Recurrence and Retreatment with SBRT - Yukinori Matsuo, MD, PhD

Surgical Approach to Treatment - Professor Hiroshi Date, MD

This program will:

  • Address state-of-the art techniques using CT and FDG-PET for diagnosis of recurrent disease
  • Provide a literature review on outcomes and toxicities of re-irradiation for local recurrence after SBRT
  • Discuss appropriate patient selection for salvage surgery

After viewing this program, attendees will be able to:

  • Evaluate the  roles of imaging modalities in differential diagnosis of local recurrence from radiation lung injury after SBRT
  • Discuss indications of re-irradiation with SBRT as a salvage treatment of local recurrence
  • Interpret pathologic findings of the resected lung for local recurrence

DOWNLOAD RECORDING

CME Information:

Financial/Commercial Relationships DISCLOSURES

A Conflict of Interest (COI) is created and exists when individuals in a position to control the content of CME, or their spouses/partners, that have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells, or distributes health care goods or services consumed by, or used, on patients that benefits the individual in any financial amount and therefore, may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected. 

 This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

IASLC CME assures that the planners/reviewers/authors/faculty/moderators/peer reviewers et. al. conflicts of interest  were identified, reviewed and resolved from all individuals involved in the development  or able to influence and control the content of this CME activity; IASLC CME assures that disclosure is given prior to an educational activity being delivered to learners.  Any individual who failed or refused to disclose relevant financial relationships was disqualified from this CME activity and removed from any of IASLC CME activity presentation.

All commercial relationships and conflicts of interest that are identified are thoroughly vetted by IASLC Ethics Committee, CME Subcommittee, and Independent reviewer. COI will be evaluated by the Board of Directors of the IASLC for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. IASLC CME is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.

CREDIT STATEMENT

IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IASLC CME designates this Internet Live Course activity for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

GOAL & PURPOSE

Stereotactic body radiation is now considered a safe and efficient treatment for small, early stage non-small cell lung cancers. For patients with locally recurrent disease following SBRT, retreatment with SBRT may be an option for selected patients, while for other patients a surgical approach may be indicated. Of 308 patients undergoing SBRT for clinical stage I NSCLC, 49 patients were identified to have isolated local recurrence and 12 patients underwent salvage surgery. Five-year survival for patients undergoing salvage surgery was 79.5% from local recurrence. Operability based on multidisciplinary conferences, rather than measurable patient characteristics, is essential for appropriate patient selection for salvage surgery.

TARGET AUDIENCE

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

DISCLAMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

COI Resolution: Ensure a balanced discussion of alternative. Do not use trade names. Do not refer to company names or logos. Do not recommend therapies.

“All planning committee members’, reviewers, planners and faculty et al. identified conflicts of interest pertaining to this activity were resolved prior to the activity.”

Thank you for your participation.

 

IASLC Financial/Commercial Relationships and Conflicts of Interest Policy

IASLC Honoraria Policy

IASLC Commercial Support Agreement (LOA)

If you are interested in obtaining the CME Credits for these sessions you must indicate this when you register for the program. CME Credit is only available for those that participate in the Live Session.

Location Local time Time zone UTC offset
New York (U.S.A. - New York) Wednesday, December 9, 2015 at 6:00:00 AM EST UTC-5 hours
Tokyo (Japan) Wednesday, December 9, 2015 at 8:00:00 PM JST UTC+9 hours
Beijing (China) Wednesday, December 9, 2015 at 7:00:00 PM CST UTC+8 hours
Shanghai (China) Wednesday, December 9, 2015 at 7:00:00 PM CST UTC+8 hours
Singapore (Singapore) Wednesday, December 9, 2015 at 7:00:00 PM SGT UTC+8 hours
Kuala Lumpur (Malaysia) Wednesday, December 9, 2015 at 7:00:00 PM MYT UTC+8 hours
Paris (France) Wednesday, December 9, 2015 at 12:00:00 Noon CET UTC+1 hour
Amsterdam (Netherlands) Wednesday, December 9, 2015 at 12:00:00 Noon CET UTC+1 hour
Moscow (Russia) Wednesday, December 9, 2015 at 2:00:00 PM MSK UTC+3 hours
Rome (Italy) Wednesday, December 9, 2015 at 12:00:00 Noon CET UTC+1 hour
Athens (Greece) Wednesday, December 9, 2015 at 1:00:00 PM EET UTC+2 hours
Prague (Czech Republic) Wednesday, December 9, 2015 at 12:00:00 Noon CET UTC+1 hour
Corresponding UTC (GMT) Wednesday, December 9, 2015 at 11:00:00 AM    

How to use the Time Zone Converter

This series is partially supported by an unrestricted grant from Elekta